Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

Table 2 Ten-years disease/mortality, children ≤59 months, multiple PCV13 catch-up scenarios, assuming no acceleration in indirect effects

	PCV13 with no catch-up	Catch-up 39%	Catch-up 87%	Cases prevented due to catch-up (39%)	Additional cases potentially prevented with increased catch-up^a
IPD	22,261	21,048	19,637	1,176	1,448
Hospitalized Pneumonia	940,580	927,831	912,141	12,749	15,690
Non-hospitalized Pneumonia	14,037,214	13,994,317	13,941,520	42,897	52,797
AOM	144,731,659	144,194,812	143,534,078	536,847	660,735
Deaths	3,141	3,116	3,084	26	32

AOM: acute otitis media; IPD: invasive pneumococcal disease; PCV13: 13-valent pneumococcal conjugate vaccine.
^aFrom 39% to 87%.

ISSN: 1471-2334